PLEKHB1: A Potential Drug Target for Various Diseases (G58473)

Target Name: PLEKHB1

NCBI ID: G58473

PLEKHB1

PLEKHB1: A Potential Drug Target for Various Diseases

PLEKHB1 (KPL1) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the PLEK family of proteins, which are known for their role in the regulation of extracellular matrix (ECM) components. PLEKHB1 has been identified as a potential drug target due to its involvement in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The PLEK family of proteins was first identified in the late 1990s based on the analysis of genomic and transcriptomic data. These proteins are characterized by the presence of a single transmembrane domain and a C-terminal region that contains a unique nucleotide sequence known as a P-loop. PLEKHB1 is a member of the PLEK family and is composed of 21 amino acid residues.

PLEKHB1 is expressed in a variety of tissues, including the brain, heart, and kidneys, and has been shown to play a role in the regulation of ECM components. For example, PLEKHB1 has been shown to be involved in the regulation of extracellular matrix (ECM) components such as collagen, which is a component of the ECM that provides structural support and contributes to tissue stiffness.

In addition to its role in ECM regulation, PLEKHB1 is also involved in several signaling pathways that are important for the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant functions of PLEKHB1 is its role in the regulation of cell adhesion. Adhesion is the process by which cells stick together to form tissues and organs. PLEKHB1 is involved in this process by helping to regulate the formation of tight junctions, which are the weakest type of cell adhesion.

In addition to its role in cell adhesion, PLEKHB1 is also involved in the regulation of several other signaling pathways that are important for the development and progression of diseases. For example, PLEKHB1 is involved in the regulation of the PI3K/Akt signaling pathway, which is important for the development and progression of cancer.

PLEKHB1 is also involved in the regulation of the TGF-β signaling pathway, which is important for the development and progression of neurodegenerative diseases. TGF-β is a transcription factor that is involved in the regulation of cellular processes that are important for the development and progression of tissues, including neural tissues.

In addition to its role in the regulation of these signaling pathways, PLEKHB1 is also involved in the regulation of several other cellular processes that are important for the development and progression of diseases. For example, PLEKHB1 is involved in the regulation of cell migration, which is the process by which cells move from one location to another in the body.

In addition to its role in cell migration, PLEKHB1 is also involved in the regulation of the cytoskeleton, which is the structure that makes up the cell's nucleus and other organelles. The cytoskeleton plays a role in the regulation of cell shape and movement, and is important for the development and progression of many diseases, including cancer.

PLEKHB1 is also involved in the regulation of the cell cycle, which is the process by which cells grow and divide. The cell cycle is important for the development and progression of many diseases, including cancer, and PLEKHB1 plays a role in regulating the cell cycle in

Protein Name: Pleckstrin Homology Domain Containing B1

The "PLEKHB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PLEKHB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets